Trials / Recruiting
RecruitingNCT06585462
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 513 | AMG 513 will be administered by SC or IV injection. |
| DRUG | Placebo | Placebo will be administered by SC or IV injection. |
| DRUG | AMG 513 | AMG 513 will be administered by SC injection. |
| DRUG | Placebo | Placebo will be administered by SC injection. |
Timeline
- Start date
- 2024-09-09
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-09-05
- Last updated
- 2026-02-13
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06585462. Inclusion in this directory is not an endorsement.